The US based CDMO, SK pharmteco, is to invest $260 million to construct a new small molecule and peptide production facility in Sejong, South Korea.

SK pharmteco plans to hire more than 300 new employees to support construction of the new 135,800 square foot facility, which will add to the four other SK pharmteco facilities in South Korea. The new plant will feature eight production trains with a capacity of tens of metric tonnes per annum, in addition to peptide R&D facilities, CGMP kilo labs, and a CGMP pilot plant for peptide manufacturing. The investment also includes construction of the shell for a sixth manufacturing plant, allowing the quick addition of future capacity.